https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-03 08:44:492025-03-03 09:14:54Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-03 08:44:492025-03-03 09:14:54Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth
Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025
Domain’s leadership will highlight advancements in its key…

Experienced Industry Leader Tom Arnold Appointed as Chief Executive Officer of ViCentra
Experienced MedTech leader to scale manufacturing, drive…

Ottimo Pharma Strengthens Leadership Team with Senior Appointments
Robert Tighe appointed as Senior Vice President of Preclinical…

Unravelling the infection enigma: Jean-Laurent Casanova’s pioneering genetic discoveries earn him the 2025 Novo Nordisk Prize
For decades, scientists believed that infections were determined…

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types
Dr. Aleix Prat, an internationally recognized leader in drug…

LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
Dr Mozayeni brings deep experience in biotech corporate strategy…

Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments
Initiative marks first investment of global health partnership…

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin…

Liva Healthcare acquires Momenta, and secures funding from new and existing investors to drive growth
Purchase of UK-based Discover Momenta and Momenta Newcastle…

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion
Financing led by CARMA FUND and RV Invest with participation…

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology
ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate…

BrightHeart Unveils Breakthrough AI Results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, Revolutionizing Prenatal Care
Paris, France – January 31, 2025, BrightHeart, a global leader…

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year
In 2024, on its 100th anniversary, the Novo Nordisk Foundation…

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
Additional funding from new investor Korys, joining existing…

Campus Kalundborg takes next step to become a leading hub for education, research and innovation within biomanufacturing and biosolutions
DKK 320 million has been awarded for the development of a new…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York